2022

Minoryx submits a marketing authorisation application for its drug leriglitazone for the treatment of X-ALD.
15/09/2022

X-linked adrenoleukodystrophy (X-ALD) is a rare, neurodegenerative disease for which there is no treatment. Mataró, Barcelona, Spain, September 14, 2022 –... Read More
Columbus VP leads the new investment round of Integra Therapeutics with €1.5M
30/03/2022

The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo... Read More